Browse All

Current Filters

CLEAR FILTER x

TITLE

ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease

Author:Giovannoni, Gavin   Airas, Laura   Bove, Riley   Cutter, Gary   Hobart, Jeremy   Kuhle, Jens   Montalban, Xavier   Tur, Carmen   Wolinsky, Jerry   Schneble, Hans-Martin   Baldinotti, Anna   Bonati, Ulrike   Giacobino, Caroline   Wang, Qing   Yang, Ke   Oh, Jiwon   

Session Name:S40: Multiple Sclerosis: Clinical Trials/Science and Real-world Evidence  

Topic:Multiple Sclerosis  

Program Number:S40.001  

Author Institution:Department of Neurology, Royal London Hospital, Barts Health NHS Trust, London, UK and Blizard Institute, Queen Mary University, London, UK, London, United Kingdom  University of Turku, Turku, Finland, Turku, Finland  UCSF Weill Institute for Neuroscience, Department of Neurology, University of California San Francisco, San Francisco, CA, USA, CA  The University of Alabama at Birmingham, School of Public Health, Birmingham, AL, USA, Birmingham, AL  Peninsula Medical School, Plymouth University, UK, Plymouth, United Kingdom  MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland, Switzerland  Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain  Queen Square MS Centre, Department of Neuroinflammation, Institute of Neurology, Faculty of Brain Sciences, University College London (UCL), London, UK/Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (CEMCAT), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, Un  Department of Neurology, University of Texas Health Science Center, Houston, TX, USA, TX  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Switzerland  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada, ON, Canada  

Efficacy and Safety of Frexalimab in Participants With Relapsing Multiple Sclerosis: 3-Year Results From the Phase 2 Open-label Extension

Author:Vermersch, Patrick   Krieger, Stephen   Wiendl, Heinz   Granziera, Cristina   Mao-Draayer, Yang   Cutter, Gary   Kalbus, Oleksandr   Staikov, Ivan   Dufek, Michal   Montalban, Xavier   Saubadu, Stephane   Luo, Xiaodong   Smyth, Brendan   Djukic, Biljana   Truffinet, Philippe   Wallstroem, Erik   Giovannoni, Gavin   

Session Name:P7: Multiple Sclerosis: Clinical Trials 1  

Topic:Multiple Sclerosis  

Program Number:P7.003  

Author Institution:University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, Lille, France  Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, United States, New York, NY  Department of Neurology and Neurophysiology, University of Freiburg, Freiburg, Germany  Brain & Mind Institute, University of Sydney, Sydney, Australia, Freiburg im Breisgau, Germany  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Autoimmunity Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States, Oklahoma City, OK  Department of Biostatistics, UAB School of Public Health, Birmingham, AL, United States, Birmingham, AL  Department of Neurology, Dnipro State Medical University, Dnipro, Ukraine, Dnipro, Ukraine  Clinic of Neurology and Sleep Medicine, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria, Sofia, Bulgaria  First Department of Neurology, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic  Multiple Sclerosis Centre of Catalonia, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain , Barcelona, Spain  Sanofi, Gentilly, France, Chilly Mazarin, France  Sanofi, Morristown, NJ, United States, Morristown, NJ  Sanofi, Cambridge, MA, United States, Cambridge, MA  Queen Mary University of London, London, United Kingdom, London, United Kingdom  

Ofatumumab Treatment Up to Eight Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Montalban, Xavier   Cohen, Jeffrey   Morrow, Sarah   Li, Jun   Carr, David   Pearce, Gregory   Solonets, Maria   Abeyewickreme, Anil   de Seze, Jérôme   Nakahara, Jin   Wiendl, Heinz   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials 2  

Topic:Multiple Sclerosis  

Program Number:P9.006  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Department of Neurology/Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, calgary, AB, Canada  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  IQVIA RDS GmbH, Frankfurt, Germany, Germany  Novartis Pharmaceuticals UK Ltd, London, United Kingdom, London, United Kingdom  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Klinik für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Freiburg, Germany, Freiburg im Breisgau, Germany  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA